RELPREMA
DEAD

Serial Number

87571121

Owner

ALLERGAN SALES, LLC

Filing Date

Aug 16, 2017

Add to watchlist:

No watchlists yet
View on USPTO

RELPREMA Trademark

Serial Number: 87571121

RELPREMA is a trademark filed by ALLERGAN SALES, LLC on August 16, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

ALLERGAN SALES, LLC (490 trademarks)

5 GIRALDA FARMS
MADISON, NJ 07940

Entity Type: 16

Trademark Details

Filing Date

August 16, 2017

Registration Date

Not Registered

Published for Opposition

December 26, 2017

Goods & Services

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceuticals and medicines for the central nervous system; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Mar 29, 2021 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 29, 2021 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 19, 2020 EXRA
SOU EXTENSION 5 GRANTED
Aug 18, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 18, 2020 AITU
SOU EXTENSION 5 FILED
Aug 14, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Aug 14, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 15, 2020 EXRA
SOU EXTENSION 4 GRANTED
Feb 13, 2020 EX4G
SOU EXTENSION 4 FILED
Feb 13, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 13, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 20, 2019 EXRA
SOU EXTENSION 3 GRANTED
Jun 18, 2019 EX3G
SOU EXTENSION 3 FILED
Jun 18, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 18, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2019 EXRA
SOU EXTENSION 2 GRANTED
Feb 8, 2019 EX2G
SOU EXTENSION 2 FILED
Feb 8, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 8, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 9, 2018 EXRA
SOU EXTENSION 1 GRANTED
Aug 7, 2018 EX1G
SOU EXTENSION 1 FILED
Aug 7, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 7, 2018 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 20, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2017 NPUB
PUBLISHED FOR OPPOSITION
Dec 26, 2017 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 6, 2017 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2017 CNSA
ASSIGNED TO EXAMINER
Nov 20, 2017 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 22, 2017 NWOS
NEW APPLICATION ENTERED
Aug 21, 2017 NWAP